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Abstract
Background: The single nucleotide polymorphisms (SNPs) in matrix metalloproteinase 1(MMP-1)play important roles in
some cancers. This study examined the associations between individual SNPs or haplotypes in MMP-1 and susceptibility,
clinicopathological parameters and prognosis of gastric cancer in a large sample of the Han population in northern China.
Methods: In this case–controlled study, there were 404 patients with gastric cancer and 404 healthy controls. Seven SNPs
were genotyped using the MALDI-TOF MS system. Then, SPSS software, Haploview 4.2 software, Haplo.states software and
THEsias software were used to estimate the association between individual SNPs or haplotypes of MMP-1 and gastric cancer
susceptibility, progression and prognosis.
Results: Among seven SNPs, there were no individual SNPs correlated to gastric cancer risk. Moreover, only the rs470206
genotype had a correlation with histologic grades, and the patients with GA/AA had well cell differentiation compared to
the patients with genotype GG (OR=0.573; 95%CI: 0.353–0.929; P=0.023). Then, we constructed a four-marker haplotype
block that contained 4 common haplotypes: TCCG, GCCG, TTCG and TTTA. However, all four common haplotypes had no
correlation with gastric cancer risk and we did not find any relationship between these haplotypes and clinicopathological
parameters in gastric cancer. Furthermore, neither individual SNPs nor haplotypes had an association with the survival of
patients with gastric cancer.
Conclusions: This study evaluated polymorphisms of the MMP-1 gene in gastric cancer with a MALDI-TOF MS method in a
large northern Chinese case-controlled cohort. Our results indicated that these seven SNPs of MMP-1 might not be useful as
significant markers to predict gastric cancer susceptibility, progression or prognosis, at least in the Han population in
northern China.
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Introduction
Gastric cancer is one of the most common leading causes of
cancer-related mortality worldwide [1]. Despite some advances in
the diagnosis and treatment of gastric cancer in the last decades,
the prognosis for patients with advanced gastric cancer remains
poor [2]. Like other cancers, the development of gastric cancer is a
multistep process with the accumulation of genetic and epigenetic
changes. The discovery and application of biomarkers that can be
incorporated with traditional cancer diagnosis, staging and
prognosis could largely help to improve early diagnosis and
patient care [3]. With the completion of the human genome
project, millions of single nucleotide polymorphisms (SNPs) have
been identified as attractive biomarkers in cancer risk assessment,
screening, staging, or grading [4].
Matrix metalloproteinases (MMPs) are an important family of
metal-dependent enzymes that are responsible for the degradation
of extracellular matrix components [5]. Molecular epidemiologic
studies have shown associations between genetic polymorphisms of
MMPs and cancer susceptibility, progression and prognosis [6–
10]. Recently, some SNPs of MMP-1 have been demonstrated to
be significantly associated with increased risk for the development
of lung cancer [6,7,11]. In breast cancer, Karolina Przybylowska
et al. found that the 2G allele of the 1G/2G MMP-1 gene
polymorphism may be responsible for lymph node (LN) metastasis
[8]. On the other hand, both studies of Hinoda Y et al. and
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increased risk of colorectal cancer [12,13]. Furthermore, a SNP in
the MMP-1 promoter was demonstrated to be correlated with
histological differentiation of gastric cancer [14]. However, other
studies showed a negative association between MMP-1 polymor-
phisms and cancer susceptibility [15,16,17]. Furthermore, most of
these studies were limited to small samples, few SNPs or
constructed haplotypes from two or three polymorphic sites.
Thus, a large sample and more polymorphic sites are critical to
understanding the role of MMP-1 SNPs in gastric cancer
development.
In the present study, in a large sample of the Han population in
northern China, we used formalin-fixed, paraffin-embedded
tissues (FFPETs)-derived DNA samples from patients and blood-
derived DNA from controls in a matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS)
method to study the potential associations between seven SNPs
(rs2071231, rs7125062, rs491152, rs470558, rs2075847, rs470206
and rs1144396) or haplotypes in MMP-1 and tumor susceptibility,
clinicopathological parameters, and survival of gastric cancer.
Materials and Methods
Subject selection
This study consisted of 404 primary gastric cancer patients and
404 controls and all subjects were from the Han population in
northern China. The subject characteristics have been described
previously [18]. Briefly, eligible patients had received radical
surgery at the First Hospital of China Medical University between
January 1998 and December 2004 and were diagnosed with
gastric cancer based on histopathological evaluation. The tumor
histological grade was assessed according to World Health
Organization criteria and tumors were staged using the 7th
edition of the TNM staging of the International Union Against
Cancer (UICC)/American Joint Committee on Cancer (AJCC)
system (2010) based on postoperative pathological examination of
the specimens. Complete pathological data were obtained
including age, gender, date of surgery, location of the primary
tumor, histologic grade, venous invasion, lymphovascular inva-
sion, depth of invasion, number of LNs retrieved, number of
metastatic LNs, and number of tumor deposits retrieved. Those (i)
with synchronous or metachronous malignant tumors, (ii) with
distant metastasis found preoperatively, (iii) who underwent
preoperative radiotherapy or chemotherapy, or (iv) with incom-
plete pathological data entries were excluded from this study.
Follow-up was completed for the entire study population until
January 2010. Two patients died in the postoperative period
(within 30 days) and 21 patients were lost to follow-up; therefore,
381 patients were included in survival analysis. Median and mean
follow-up periods were 90.0 months and 93.3620.24 months
(range: 61–136 months), respectively. The following data were
obtained for all patients: date of death (if applicable), cause of
death (if applicable), and date of follow-up. The primary endpoint
was cancer-specific survival duration from the date of gastric
cancer diagnosis to the date of death. The 5-year survival rate of
the 404 patients was 54.2%.
404 blood samples of the control group were obtained from
cancer-free individuals that were randomly selected based on
physical examinations during December 2009 to August 2011, and
this group was believed to be a good representation of the
population in this region. The selection criteria included no
individual history of cancer, frequency matching to cases on sex
and age and individuals were unrelated ethnic Han Chinese. The
samples (Ethylene Diamine Tetraacetic Acid [EDTA] anticoagu-
late) were stored at 220uC within 30–40 minutes, and then moved
to a freezer at 280uC within 2 or 3 days after collection.
Ethics statement
The study was approved by the Research Ethics Committee of
China Medical University, China. Written informed consent was
obtained from all people before participating in the study.
DNA extraction
Genomic DNA was extracted from FFPET samples in the case
group. Sections with a thickness of 8 mm and a surface area of up
to 250 mm
2 were prepared with a microtome and DNA was
isolated from 6 sections to 12 sections, depending on the tissue size
and cell counts. The microtome was cleaned and the blades were
changed to avoid intersample contamination. DNA extraction
from FFPETs was performed with a QIAampH DNA FFPE Tissue
Kit (Qiagen, Hilden, Germany) [19], following the procedures
described by the manufacturer and our previous work [18]. About
2–10 mg of DNA was recovered in 50 ml final solution and was
stored at 280uC.
Genomic DNA was extracted from blood samples from the
control group with the Universal Genomic DNA Extraction Kit
Ver.3.0 (TAKARA) according to the manufacturer’s instructions
and our previous work [18]. About 2–6 mg of DNA was recovered
in TE and was stored at 280uC.
Selection of candidate SNPs
The study included seven SNPs in MMP-1, which were taken
from the NCBI SNPs database and the HapMap database. We
selected SNPs across the gene loci to ensure a high density of
markers and to provide adequate characterization of haplotype
diversity [6]. All selected SNPs were required to have a minor
allele frequency $5%. We therefore selected seven SNPs:
rs2071231 (intron), rs7125062 (intron), rs491152 (intron),
rs470558 (exon), rs2075847 (59UTR), rs470206 (59 UTR) and
rs1144396 (Fig. 1A).
SNPs analysis and validation
SNPs were genotyped using the MALDI-TOF MS system
(MassARRAY; Sequenom, San Diego, CA, USA) with primers
and probes (Table S1) as previously described [19,20]. To ensure
the typing quality, 1% positive samples (YanHuang cell strain)
were incorporated into every genotyping plate to validate the
reliability of the primers and 1% negative samples (water with no
DNA) were used to monitor contamination. 5% random samples
were tested in duplicate by different persons and the reproduc-
ibility was 100%. The laboratory personnel were blinded to the
sample arrangement during the process. MALDI-TOF MS
analysis were according to Justenhoven et al. [21] and the main
process included PCR amplification (GeneAmpH PCR System
9700 Dual 384-Well Sample Block Module, Sequenom), shrimp
alkaline phosphatase treatment (Sequenom), base extension
reactions, salt removal with resin, SpectroCHIP dispensing (384-
well SpectroCHIP microarray, Sequenom). Allelic discrimination
was obtained by analysis with a MassARRAY Analyzer Compact
mass spectrometer (MT9). Finally, data analysis were performed
using MassArray Typer Analyzer software 4.0 (Sequenom, San
Diego, CA) [22].
Linkage disequilibrium (LD) block determination and
haplotype construction
Haploview 4.2 software was used to evaluate LD and construct
haplotypes as described previously [6]. LD between the seven
The Effect of SNPs of MMP-1 in Gastric Cancer
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statistic. The structure of the LD block was examined using the
method of Gabriel et al. [23], using the 80% confidence bounds of
D9 to define sites of historical recombination between SNPs.
Haplotypes were constructed from genotype data in the full-size
case-control panel within blocks using an accelerated expectation-
maximization algorithm method with Haploview 4.2 software
[6,24]. Furthermore, we made SNP genotype combinations to find
their association with gastric cancer risk [25].
Statistical analysis
A two-sided chi-square (x2) test was used to estimate population
distribution characteristics, compare differences in allelic and
genotypic frequencies between cases and controls and estimate
associations between individual SNPs and clinicopathological
parameters. To assess significance, a permutation procedure
(1,000 tests) was used to correct the P value of single-locus
association results [6]. A permutation test is a type of statistical
significance test in which the distribution of the test statistic under
the null hypothesis is obtained by calculating all possible values of
the test statistic under rearrangements of the labels on the
observed data points. Moreover, the Bonferroni correction was
used for multiple testing correction [26]. Logistic regression was
used to analyze the association between genotype frequencies and
gastric cancer risk, adjusted for sex and age. Survival analyses were
done with the log-rank test and Cox proportional hazards model.
The Haploview 4.2 software package was used to: estimate pair-
wise LD, detect departure from the Hardy–Weinberg equilibrium,
construct haplotypes, calculate haplotype frequencies and estimate
associations between haplotypes and gastric cancer risk. We also
used Haplo.states software to assess associations between haplo-
types and clinicopathologic features [6,27]. The THEsias software
based on Cox proportional hazards survival regression in
haplotype-based association analysis using the Stochastic-EM
algorithm was used to produce survival analysis of haplotypes
[28]. Because of multiple hypothesis testing, the P value for
significance was adjusted conservatively by Bonferroni correction
to ,0.007 (0.05/7)
Figure 1. SNPs in the region of MMP-1 gene located in chromosome 11q22. A, MMP-1 gene structure. Filled boxes represent the exons
(59R39). Arrows show the locations of SNPs. B: Mapping of the block structure of the seven SNPs generated by Haploview. The value within each
square in the triangle plot represents the pairwise correlation between SNPs (measured as D9) defined by the upper left and the upper right sides of
the Squares. The Squares without a number correspond to D9=1. Shading represents the magnitude and significance of pairwise LD, with a red-to-
white gradient reflecting higher to lower LD values. The frequency of each common haplotype within a block is to the right of the haplotype.
doi:10.1371/journal.pone.0038002.g001
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Subject characteristics
As shown in Table 1 and previous work, the average age was
56.67611.92 y and the percentage of males was 70.54% in the
case group. The average age of the control group was
56.91611.48 y and the percentage of males was 70.54%. There
was no statistically significant difference in the distribution of sex
and age between patients and controls (all P=1.00). Moreover, of
the 404 patients, 85 (21.04%) had stage I gastric cancer, 107
(26.49%) had stage II gastric cancer, and 212 (52.48%) had stage
III gastric cancer (Table 1). The other clinicopathological
parameters of gastric cancer patients are shown in Table 1.
Table 1. Distributions of selected characteristics in gastric cancer cases and controls (n=404 for both case and control groups).
Variable Patients (n=404) No. (%) Controls (n=404) No.(%) P
a
Sex 1.0
Male 285(70.54) 285(70.54)
Female 119(29.46) 119(29.46)
Age at diagnosis 1.0
#40 30 (7.43) 30 (7.43)
41–50 94(23.27) 94(23.27)
51–60 111(27.48) 111(27.48)
61–70 122(30.20) 122(30.20)
.70 47(11.63) 47(11.63)
Tumor stage
Ia 45(11.1)
Ib 40(9.9)
IIa 58(14.4)
IIb 49(12.1)
IIIa 57(14.1)
IIIb 115(28.5)
IIIc 40(9.9)
IV 0(0)
pT category
T1 59(14.6)
T2 70(17.3)
T3 193(47.8)
T4 82(20.3)
Lymph node metastasis
Negative 127(31.4)
Positive 277(68.6)
Borrmann type
Borr1 64(15.8)
Borr2 45(11.1)
Borr3 266(65.8)
Borr4 29(7.2)
Histologic grade
Well 94(23.3)
Poor 310(76.7)
Venous invasion
Negative 400(99.0)
Positive 4(1.0)
Lymphovascular invasion
Negative 303(75.0)
Positive 101(25.0)
aTwo-sided x
2 test.
doi:10.1371/journal.pone.0038002.t001
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All the SNPs were polymorphic with minor allele frequencies
.10% and genotype distributions were all in agreement with
Hardy-Weinberg equilibrium (data not shown). The success rates
were high in the case group (98.27–100%) and control group
(99.50–100%; Table S2). Then, we used Haploview 4.2 software
to evaluate LD and construct haplotypes. LD was observed across
rs2071231, rs7125062, rs491152 and rs470558 (all D $0.99), and
these four SNPs constructed block 1. Block 1 covered 5.0 kb and
contained 4 common haplotypes: TCCG, GCCG, TTCG and
TTTA (frequency range: 0.127–0.500), which represented ap-
proximately 99.9% of the subjects (Fig.1B).
Associations between individual SNPs and gastric cancer
risk, clinicopathological parameters and survival
As shown in Table 2, there was no statistical difference in the
allele distribution between patients and controls (P.0.007 and
P.0.007 after a permutation test for allelic frequencies and
Bonferroni correction). Moreover, there was no association
between genotype distributions of the seven SNPs in MMP-1
and the risk of gastric cancer (P.0.007 and P.0.007 after being
adjusted for sex and age for genotypic frequencies, Table 3).
The genotypes of individual SNPs were evaluated for associa-
tions with the clinicopathological parameters. Table 4 showed that
rs470206 genotypes had a correlation with histologic grades, and
the patients with GA/AA had well cell differentiation compared to
the patients with genotype GG (OR=0.573; 95%CI: 0.353–
0.929; P=0.023). However, it was not significant after Bonferroni
correction. The other genotypes of SNPs had no significant
correlations with clinicopathological parameters in gastric cancer.
In univariate analysis, Borrmann type, pT category, lymph
node metastasis, lymphovascular invasion and TNM stage were
demonstrated to be significant prognostic factors (Table 5).
However, the statistical results revealed that all genotypes of the
seven SNPs had no associations with survival of patients with
gastric cancer (all P.0.007, Table 5).
Associations between haplotypes or SNP genotype
combinations and gastric cancer risk, clinicopathological
parameters and survival
Using Haploview 4.2 software, we constructed a four-marker
haplotype block, which contained four common haplotypes:
TCCG, GCCG, TTCG and TTTA. All four common haplotypes
had no correlation with gastric cancer risk (P.0.007 and P.0.007
after a permutation test; Table S3). Moreover, we did not find any
relationship between these four common haplotypes and clinico-
pathological parameters in gastric cancer (all P.0.007, Table S4).
Furthermore, the result of univariate analysis showed no
association between all the haplotypes and survival of patients
with gastric cancer (all P.0.007, Table S5).
Then, we made SNP genotype combinations to find their
association with gastric cancer risk. Among all combinations,
genotype combinations of two SNPs (rs2071231 and rs470206)
had four subgroups: TA, TG, GG and AA. Although the LD
between the two SNPs did not exist and the four subgroups had no
correlation with gastric cancer risk (P=0.523), the patients with
TA had well cell differentiation compared to the patients with
genotype TG (OR=0.561; 95%CI: 0.357–0.881; P=0.022).
However, it was not significant after Bonferroni correction.
Furthermore, all subgroups had no associations with survival of
patients with gastric cancer (all P.0.007). The other genotype
combinations had no significant results.
Discussion
The degradation of extracellular matrix and basement mem-
brane by MMPs is one of the most important regulatory elements
in many physiological and pathological processes of tumor
invasion and metastasis [5]. The majority of previous studies have
focused on the relation between SNPs and MMP-2 and MMP-9.
Furthermore, some SNPs of MMP-1 have been demonstrated to
be significantly associated with increased risk for the development
of lung cancer, breast cancer and colorectal cancer [6–8,11–13].
However, other studies showed a negative association between
MMP-1 polymorphisms and cancer susceptibility [15–17]. More-
over, in gastric cancer, most of the studies on MMP-1 have only
focused on the importance of the SNP (21607 1G/2G) in the
promotor in relatively small samples. Jin X et al. reported that
there was no association of the MMP-1 promoter polymorphism
(21607 1G/2G) with susceptibility to gastric cardiac adenocarci-
noma in northern China (183 patients) [15]. However, a study on
a Japanese population (215 patients) showed that, although the
presence of the 2G allele (21607) in the MMP-1 promoter did not
enhance the risk of gastric cancer, it may be involved in
differentiation of gastric cancer [14]. Hence, a large sample and
more polymorphic sites are critical for understanding the role of
MMP-1 SNPs in gastric cancer development.
Table 2. Allele frequencies of seven SNPs in MMP-1 among patients and controls.
SNP
a Chromosome Position
b Allele Risk allele No.allele(%) P
c P
d
Patients Controls
rs2071231 102661276 G/T G 168(20.9) 159(19.7) 0.560 0.988
rs7125062 102663503 C/T C 570(70.5) 568(70.3) 0.913 1.000
rs491152 102666043 C/T T 103(12.8) 102(12.6) 0.925 1.000
rs470558 102666316 A/G A 105(13.2) 102(12.7) 0.764 0.999
rs2075847 102669824 C/T T 625(78.7) 612(75.7) 0.156 0.591
rs470206 102671178 A/G A 132(16.3) 117(14.5) 0.301 0.862
rs1144396 102679052 A/C C 536(66.3) 528(65.3) 0.675 0.996
aAccording to National Center for Biotechnology Information SNP database rs number.
bChromosome Positions are from National Center for Biotechnology Information Build 37.3.
cTwo-sided x
2 test.
dAfter 1,000 permutation tests.
doi:10.1371/journal.pone.0038002.t002
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across MMP-1 to ensure a high density of markers and to provide
adequate characterization of haplotype diversity. Moreover, we
selected 404 patients and 404 controls that had the same
distributions for sex and age. On the other hand, until now, most
of the SNPs were studied by restriction fragment length
polymorphism (RFLP) assay [29], TaqMans [19], DHPLC [30],
MALDI-TOF MS [6,20] and pyrosequencing analysis [31].
Currently, the MALDI-TOF MS method, offering approximately
100% accuracy for SNP genotyping, is considered as a gold
standard [19,32]. Moreover, previous reports showed that there
were no allelic frequency differences between FFPET-derived
DNA and blood-derived DNA from the same individual through
several methods, including MALDI-TOF MS [33–35]. Therefore,
genotyping of FFPET-derived DNA by MALDI-TOF MS is
reliable and reproducible. Our results also showed high success
rates ranging between 98.27% and 100% (mean: 99.43%), which
were in accordance with previous reported data [19,32,33].
Among seven SNPs, Sun et al. showed that risk allelic
frequencies of rs7125062, rs2075847 and rs470206 were higher
in patients with lung cancer than in controls [6]. But, in the
present study, there were no individual SNPs correlated to gastric
Table 3. Associations between genotype distributions of seven SNPs in MMP-1 and the risk of gastric cancer.
Genotype Controls Patients OR(95% CI)
a OR(95% CI)
b P
a P
b
No. (%) No. (%)
rs2071231 403 402 0.482 0.481
TT 266(66.0) 253(62.9) 1 1
GT 115(28.5) 130(32.3) 1.189 (0.877–1.611) 1.189 (0.877–1.612) 0.266 0.265
GG 22(5.5) 19(4.7) 0.908 (0.480–1.718) 0.909 (0.480–1.720) 0.767 0.769
GT+GG 137(34.0) 149(37.1) 1.143 (0.857–1.526) 1.144 (0.857–1.527) 0.363 0.361
rs7125062 404 404 0.839 0.824
CC 200(49.5) 198(49.0) 1 1
CT 168(41.6) 174(43.1) 1.046 (0.784–1.397) 1.046 (0.783–1.397) 0.760 0.763
TT 36(8.9) 32(7.9) 0.898 (0.536–1.503) 0.889 (0.530–1.490) 0.682 0.655
CT+TT 204(50.5) 206(51.0) 1.020 (0.774–1.344) 1.018 (0.772–1.342) 0.888 0.901
rs491152 404 403 0.936 0.922
CC 310(76.7) 307(76.2) 1 1
CT 86(21.3) 89(22.1) 1.045 (0.747–1.462) 1.045 (0.747–1.462) 0.797 0.799
TT 8(2.0) 7(1.7) 0.884 (0.317–2.466) 0.857 (0.305–2.402) 0.813 0.769
CT+TT 94(23.3) 96(23.8) 1.031 (0.745–1.428) 1.028 (0.743–1.424) 0.853 0.866
rs470558 402 398 0.864 0.853
GG 308(76.6) 300(75.4) 1 1
GA 86(21.4) 91(22.9) 1.086 (0.777–1.519) 1.086 (0.777–1.518) 0.628 0.629
AA 8(2.0) 7(1.8) 0.898 (0.322–2.508) 0.876 (0.312–2.456) 0.838 0.801
GA+AA 94(23.4) 98(24.6) 1.070 (0.774–1.481) 1.068(0.772–1.478) 0.681 0.690
rs2075847 404 397 0.345 0.352
TT 231(57.2) 244(61.5) 1 1
TC 150(37.1) 137(34.5) 0.865 (0.645–1.159) 0.867 (0.647–1.163) 0.331 0.342
CC 23(5.7) 16(4.0) 0.659 (0.339–1.278) 0.659 (0.340–1.279) 0.217 0.218
TC+CC 173(42.8) 153(38.5) 0.837 (0.631–1.110) 0.840 (0.633–1.114) 0.218 0.225
rs470206 404 404 0.314 0.319
GG 292(72.3) 283(70.0) 1 1
GA 107(26.5) 110(27.2) 1.061 (0.776–1.450) 1.060 (0.775–1.448) 0.711 0.717
AA 5(1.2) 11(2.7) 2.270 (0.779–6.616) 2.257 (0.774–6.580) 0.133 0.136
GA+AA 112(27.7) 121(30.0) 1.115 (0.822–1.512) 1.113 (0.821–1.510) 0.485 0.491
rs1144396 404 404 0.883 0.888
CC 169(41.8) 176(43.6) 1 1
CA 190(47.0) 184(45.5) 0.930 (0.694–1.246) 0.930 (0.694–1.247) 0.626 0.629
AA 45(11.1) 44(10.9) 0.939 (0.589–1.496) 0.948 (0.594–1.512) 0.791 0.822
CA+AA 235(58.2) 228(56.4) 0.932 (0.705–1.231) 0.934 (0.706–1.234) 0.619 0.630
aData were calculated by unconditional logistic regression.
bData were calculated by unconditional logistic regression, and adjusted for sex, age.
Abbreviation: OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0038002.t003
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histologic grades, and the patients with GA/AA had well cell
differentiation compared to the patients with genotype GG. This
result was similar to the polymorphic sites (21607 1G/2G), which
may be involved in differentiation of gastric cancer [14].
Furthermore, some studies revealed that the MMP-1 promoter
polymorphism (21607 1G/2G) has an association with prognosis
in tongue cancer [36], breast cancer [37] and colorectal cancer
[38]. However, we did not find any individual SNPs correlated
with prognosis in gastric cancer in our study.
SNPs are stably inherited, highly abundant and show diversity
within and among populations, which are thought to be attractive
biomarkers. However, the application of individual SNPs has been
limited because they have low penetrance and their effects are
relatively difficult to identify. Therefore, the importance of
haplotype information has been increasing to link DNA sequence
variation with disease [6,18,39]. In our study, we constructed a
four-marker haplotype block that contained 4 common haplo-
types: TCCG, GCCG, TTCG and TTTA, which were consistent
with the study of Sun et al. [6]. Their study showed haplotype
TTCG had a frequency that was significantly different between
patients and controls. Moreover, haplotype TTCG had an
increased risk for distant metastasis of lung cancer and, in contrast
with haplotype TTCG, haplotype TTTA showed a protective
effect against lung cancer progression [6]. However, in our study,
all four common haplotypes had no correlation with gastric cancer
risk and we did not find any relationship between these haplotypes
and clinicopathological parameters in gastric cancer. Furthermore,
the result of univariate analysis showed no association between all
the haplotypes and survival of patients with gastric cancer. Until
now, an increasing number of studies have focused on the
association between SNPs and disease, but even with the same
SNP, the results were usually different. More and more studies
revealed that different results could be mainly attributable to
various combinations of factors, such as disease heterogeneity,
population, environment, allelic frequencies and/or LD differenc-
es, tissue source used, sample sizes, detection technique and so on.
Interestingly, although the LD between rs2071231 and
rs470206 did not exist, we still made SNP genotype combinations
according to the study of Ostrovsky O et al. [25]. We found that,
compared to the patients with genotype TG, the patients with TA
had well cell differentiation. However, the frequency of this type of
SNP genotype combination was very low in the population.
In conclusion, this study evaluated polymorphisms of the MMP-
1 gene in gastric cancer with a MALDI-TOF MS method and
archived FFPETs in a large northern Chinese case-controlled
cohort. Although our results were negative, this study first
indicated that the SNPs (rs2071231, rs7125062, rs491152,
rs470558, rs2075847, rs470206 and rs1144396) of MMP-1 might
not be useful as significant markers to predict gastric cancer
susceptibility, progression or prognosis, at least in the Han
Table 5. Univariate analysis of the prognostic factors for
patients with gastric cancer.
N
a 5-YSR
b(%) P
c
rs2071231 0.583
TT 237 53.9
GT+GG 142 54.8
rs7125062 0.240
CC 189 50.7
CT+TT 192 57.6
rs491152 0.150
CC 292 51.9
CT+TT 88 61.0
rs470558 0.150
GG 285 52.0
GA+AA 90 60.7
rs2075847 0.398
TT 229 52.4
TC+CC 145 55.7
rs470206 0.070
GG 266 51.0
GA+AA 115 61.4
rs1144396 0.821
CC 165 53.7
CA+AA 216 54.5
Age 0.175
#60 229 57.1
.60 152 49.6
Sex 0.416
Male 272 55.2
Female 109 51.6
Borrmann type ,0.001
Borr1+2 103 81.6
Borr3+4 278 43.8
Histologic grade 0.441
Well 88 55.1
Poor 293 53.9
pT category ,0.001
T1 58 94.8
T2 68 73.5
T3 181 46.6
T4 74 21.8
Lymph node metastasis ,0.001
Negative 122 86.1
Positive 259 38.7
Venous invasion 0.280
Negative 377 54.5
Positive 4 25.0
Lymphovascular invasion ,0.001
Negative 287 60.1
Positive 94 36.0
TNM stage ,0.001
Table 5. Cont.
N
a 5-YSR
b(%) P
c
I 83 91.6
II 101 74.2
III 197 26.6
aNumber of patients
b5-year accumulative survival rate
cP values were made by log-rank test
doi:10.1371/journal.pone.0038002.t005
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provide the significant information to other scientists doing cancer
research to eliminate these seven SNPs as diagnostic markers for
gastric cancer.
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